Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against BioVie Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors [1] Summary by Relevant Sections Allegations - The class action complaint alleges that during the Class Period from August 5, 2021, to November 29, 2023, BioVie made materially false and misleading statements and failed to disclose adverse facts about its business and operations [2] - Specific allegations include: - Lack of proper oversight of the Phase 3 clinical trial [2] - Negative impact of the COVID-19 pandemic on the trial's oversight [2] - Increased risk of unreliable data due to reliance on contract research organizations, leading to significant patient exclusions from the trial [2] - Failure of the Phase 3 clinical trial to meet its primary endpoints due to these exclusions [2] - Misleading statements regarding BioVie's business, operations, and compliance with current good clinical practices [2] Contact Information - Long-term stockholders of BioVie are encouraged to reach out for more information regarding the claims or their rights [3] - Contact can be made via email or telephone, with no cost or obligation to the stockholders [3] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents investors in various complex litigations across state and federal courts [4]
BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm